Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3
Clinical progression of Alzheimer’s disease is characterized by impairment in cognition and function.
To assess the relationship between cognitive and functional impairment in mild Alzheimer’s disease.
Spearman’s rank correlations between cognitive and functional measures were calculated. Autoregressive cross-lagged panel analyses were used to determine the temporal relationship between cognitive and functional decline.
Post-hoc analysis of clinical trial data.
Placebo-treated patients with mild Alzheimer’s disease from the Phase 3 solanezumab study EXPEDITION 3.
Cognitive and functional measures were assessed at baseline and at six post-baseline time points through Week 80.
Correlation between cognitive and functional measures was 0.41 at baseline and 0.65 at Week 80. Autoregressive cross-lagged panel analysis demonstrated that cognitive impairment preceded and predicted subsequent functional decline, but functional scores did not predict cognitive outcomes.
This study supports the hypothesis that functional impairment predictably follows cognitive decline in mild Alzheimer’s disease dementia.
Key wordsCognition function Alzheimer’s disease correlation
Unable to display preview. Download preview PDF.
- 2.Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270–279.CrossRefPubMedPubMedCentralGoogle Scholar
- 4.McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:263–269.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med [In press].Google Scholar
- 11.Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S13–S21.CrossRefPubMedGoogle Scholar